An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
The study is pilot, observational, retrospective, Italian multicenter study.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Histologically confirmed diagnosis of R/R DLBCL.
2. Patientswho received at least one dose of tafasitamab in association with lenalidomide under the NPP (D.M. 7 Sep 2017), between April 2022 and December 2022.
3. Age ≥ 18 years at enrollment.
4. Signature of written informed consent (if applicable).
Exclusion Criteria:
1\) R/R DLBCL patients who received tafasitamab in association with lenalidomide in a clinical trial context.
Primary outcome measure(s)
overall response rate (ORR) — through study completion, an average of 2 years ORR as the sum of complete response \[CR\] and partial response \[PR\] rate. The study aims to retrospectively evaluate the effectiveness of tafasitamab in association with lenalidomide in patients with R/R DLBCL treated with at least one dose of tafasitamab in association with lenalidomide under the NPP.
Trial sites (11)
Facility
City
Region
Status
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna
Bologna
Recruiting
AO Sant'Anna e San Sebastiano di Caserta
Caserta
Caserta
Recruiting
A.R.N.A.S. Garibaldi
Catania
Catania
Recruiting
Azienda Ospedaliera Universitaria Arcispedale S. Anna
Ferrara
Italy
Recruiting
Azienda Ospedaliero Universitaria Careggi
Florence
Italy
Recruiting
Irccs Ospedale San Raffaele
Milan
Italy
Recruiting
Azienda Ospedaliero-Universitaria Maggiore della Carità
Novara
Italy
Recruiting
Azienda Ospedaliera Villa Sofia Cervello
Palermo
Italy
Recruiting
Ospedale Guglielmo da Saliceto di Piacenza
Piacenza
Italy
Recruiting
IRCCS- Istituto Nazionale Tumori Regina Elena
Roma
Italy
Recruiting
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma
Italy
Recruiting
More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.